Lupin (500257) Q4 96/97 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 96/97 earnings summary
16 Oct, 2026Executive summary
FY ended 31 Jul 1997: sales/income from operations rose to Rs 9,208.16 lakh from Rs 6,852.67 lakh; net profit increased 81% to Rs 686.54 lakh.
Higher productivity and cost-reduction measures supported growth; the current year was expected to perform better following recent productivity improvements.
Financial highlights
Operating profit before interest, depreciation and tax increased 45% to Rs 2,336.04 lakh from Rs 1,615.53 lakh.
Interest expense rose to Rs 1,187.89 lakh from Rs 817.93 lakh; depreciation increased to Rs 461.61 lakh from Rs 418.41 lakh.
Profit for the year was Rs 686.54 lakh, compared with Rs 379.19 lakh; other income was Rs 37.65 lakh versus Rs 49.54 lakh.
Outlook and guidance
Current-year performance was expected to improve further, citing recent productivity gains.
A technology improvement plan was underway to address global competition; opportunities to broaden the product portfolio were being evaluated to support sustainable profitability.
Latest events from Lupin
- Sales rose 22% and profit 65%, boosted by Perindopril IP income and formulations growth.500257
Q4 06/07 - Net profit more than doubled as US launches and domestic formulations accelerated growth.500257
Q4 05/06 - Record profit and export-led growth funded a research pivot toward post-2005 opportunities.500257
Q4 01/02 - Exports and APIs drove growth as domestic formulations faced pricing pressure.500257
Q4 02/03 - Revenue rose 22%, adjusted profit doubled, and US market entry took hold.500257
Q4 03/04 - Net profit rose 14.27% as Rifampicin output grew despite pricing pressure and a plant shutdown.500257
Q4 98/99 - Merger-led growth lifted FY 2000-01 turnover to Rs 902.85 crore and PAT to Rs 60.02 crore.500257
Q4 00/01 - Higher Rifampicin output lifted profit 59%; tax and pricing issues remained.500257
Q4 97/98 - Fuel inflation and price competition squeezed profits as product diversification became a priority.500257
Q4 99/00